Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Perseid Therapeutics logo — The future of autoimmune disease and transplantation treatme...

Perseid Therapeutics

The future of autoimmune disease and transplantation treatment with next-generation CTLA4-Ig technology.

Founded 2009 Biotechnology

General Information

Company Name Perseid Therapeutics
Founded Year 2009
Industries Biotechnology
Social

Get notified when Perseid Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Perseid Therapeutics

Perseid Therapeutics is a biotechnology startup with a focus on advancing treatment for autoimmune diseases and transplantation. Established in 2009, the company has emerged from a collaboration between Maxygen, Inc. and Astellas Pharma Inc. The firm is primarily known for its next-generation CTLA4-Ig technology, also referred to as MAXY-4, which holds potential for revolutionizing the treatment of autoimmune diseases and transplantation. A key highlight is the agreement in which Astellas has obtained global commercialization rights for MAXY-4, an indication of the promising nature of the technology. This focus on the global market indicates a vast potential for growth and impact. With a heightened emphasis on addressing unmet medical needs in the field of biotechnology, Perseid Therapeutics stands as a significant player in advancing therapeutic solutions for complex medical conditions. Overall, the innovative technology and the collaboration with a prominent industry player underscore the potential for significant breakthroughs in autoimmune disease and transplantation treatment. This positioning could make Perseid Therapeutics an attractive prospect for venture capital investment, given the potential for substantial impact and growth within the biotechnology industry.

Taxonomy: Autoimmune Disease, Transplantation, Protein Pharmaceuticals, CTLA4-Ig, Maxygen, Astellas Pharma, Therapeutics, Drug Development, Joint Venture, Global Commercialization, Next-Generation Technology

No funding data available for Perseid Therapeutics yet.

Get notified when Perseid Therapeutics raises funding

Perseid Therapeutics Alternatives & Competitors

Perseid Therapeutics vs
Kanyos Bio
Kanyos Bio United States

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for...

Series Unknown
1 employees
Biotechnology, Health Care
Perseid Therapeutics vs
Nanna Therapeutics
Nanna Therapeutics United Kingdom

Disease-modifying Medicines

Grant
20 employees
AI, Biotechnology
Perseid Therapeutics vs
Agensys
Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates...

Series D
Biotechnology, Health Care

FAQ About Perseid Therapeutics

The future of autoimmune disease and transplantation treatment with next-generation CTLA4-Ig technology.
Perseid Therapeutics was founded in 2009.
Perseid Therapeutics operates in the following industries: Biotechnology.
Top alternatives and competitors to Perseid Therapeutics include Kanyos Bio, Nanna Therapeutics, Agensys, Versado Training, Evec. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Perseid Therapeutics and Kanyos Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Perseid Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy